Pay in 4 interest-free payments of $6.89 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Beyond gastrointestinal effects, clinical data and class-level evidence from licensed incretin agents (semaglutide, tirzepatide) have flagged concerns regarding: Heart rate elevation: Increases in resting heart rate are a recognised class effect of GLP-1 receptor agonists, documented in the SmPCs for semaglutide (Wegovy) and tirzepatide (Mounjaro)
DPP-4 inhibitors carry a minimal risk of hypoglycemia and gastrointestinal symptoms
Keatings argument was straightforward: as GLP-1s become more accessible, through lower pricing and the rollout of pill formats like orforglipron, the addressable population for entry-level fitness expands rather than contracts
/ month $180.00 Original price was: $180.00.$100.00Current price is: $100.00
"Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study." Diabetes, Obesity and Metabolism
US$ 29.00
US$ 28.16
US$ 24.06
US$ 21.14
US$ 27.19
